NASDAQ:HOTH Hoth Therapeutics (HOTH) Stock Price, News & Analysis → Biden replacement revealed? (From Paradigm Press) (Ad) Free HOTH Stock Alerts $1.21 -0.02 (-1.63%) (As of 05/3/2024 ET) Add Compare Share Share Today's Range$1.16▼$1.2750-Day Range$1.15▼$1.6552-Week Range$0.99▼$4.30Volume73,397 shsAverage Volume37,519 shsMarket Capitalization$5.92 millionP/E RatioN/ADividend YieldN/APrice Target$4.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestSocial Media Get Hoth Therapeutics alerts: Email Address Hoth Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside230.6% Upside$4.00 Price TargetShort InterestHealthy3.39% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.65) to ($1.14) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.10 out of 5 stars 3.5 Analyst's Opinion Consensus RatingHoth Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageHoth Therapeutics has only been the subject of 1 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted3.39% of the float of Hoth Therapeutics has been sold short.Short Interest Ratio / Days to CoverHoth Therapeutics has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Hoth Therapeutics has recently decreased by 32.78%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldHoth Therapeutics does not currently pay a dividend.Dividend GrowthHoth Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for HOTH. Previous Next 0.0 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 1 news article for Hoth Therapeutics this week, compared to 1 article on an average week.Search InterestOnly 1 people have searched for HOTH on MarketBeat in the last 30 days. This is a decrease of -80% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Hoth Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -75% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Hoth Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.29% of the stock of Hoth Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 7.08% of the stock of Hoth Therapeutics is held by institutions. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Hoth Therapeutics are expected to grow in the coming year, from ($1.65) to ($1.14) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Hoth Therapeutics is -0.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Hoth Therapeutics is -0.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioHoth Therapeutics has a P/B Ratio of 0.60. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Paradigm PressBiden replacement revealed?A former CIA insider just announced a disturbing prediction… Biden will withdraw as the Democrat nominee on June 13.See his shocking evidence in this new report About Hoth Therapeutics Stock (NASDAQ:HOTH)Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation, which is in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-004 for treatment of asthma and allergies using inhalational administration; HT-003 for the treatment of acne and psoriasis, as well as inflammatory bowel diseases; and HT-002, a novel peptide for treating COVID-19. The company is also developing BioLexa Platform, a proprietary, patented, drug compound platform which is in Phase I clinical trial for the treatment of eczema; and HT-005 for treating patients with lupus, as well as a diagnostic device through a mobile device. The company has license agreements with the George Washington University; Isoprene Pharmaceuticals, Inc.; Virginia Commonwealth University; the North Carolina State University; Chelexa BioSciences, Inc. and the University of Cincinnati; Zylö Therapeutics, Inc.; and Voltron Therapeutics, Inc. It also has a research collaboration agreement with Weill Cornell Medicine to develop HT-003. Hoth Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York.Read More HOTH Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart HOTH Stock News HeadlinesMay 1, 2024 | prnewswire.comHoth Therapeutics to Attend EF Hutton Annual Global Conference, May 15, 2024April 12, 2024 | msn.comHoth Therapeutics files to sell 5.03M shares of common stock for holdersMay 4, 2024 | Colonial Metals (Ad)The Gold Grab of the CenturyWhen central banks buy gold… The rich buy right along with them. And central banks are buying at breakneck pace. Last year… 1,037 tons. Just 45 tons less than the record set two years ago.April 2, 2024 | msn.comThe Brickyard, Carlisle to welcome popular rock band Elias T HothMarch 27, 2024 | prnewswire.comHoth Therapeutics Announces Exercise of Warrants for $4.2 Million Gross ProceedsMarch 27, 2024 | prnewswire.comHoth Therapeutics' Wholly Owned Subsidiary Merveille.ai, Advances AI-Driven Discovery for Obesity TreatmentMarch 19, 2024 | marketwatch.comHoth Therapeutics Shares Soar on Positive Data from Alzheimer's StudyMarch 19, 2024 | msn.comWhy Is Alzheimer's-Focused Hoth Therapeutics Stock Trading Higher On Tuesday?May 4, 2024 | Colonial Metals (Ad)The Gold Grab of the CenturyWhen central banks buy gold… The rich buy right along with them. And central banks are buying at breakneck pace. Last year… 1,037 tons. Just 45 tons less than the record set two years ago.March 19, 2024 | finanznachrichten.deHoth Therapeutics, Inc.: Hoth Therapeutics Announces Positive Data In Completed Study of Alzheimer's Disease Pre-Clinical Treatment with HT-ALZMarch 19, 2024 | msn.comGraphite Bio, SCWorx, Acurx Pharmaceuticals among healthcare moversMarch 19, 2024 | markets.businessinsider.comHoth Therapeutics: Pre-clinical Research Shows HT-ALZ's Profound Impact On Alzheimer's PathologyMarch 19, 2024 | msn.comHoth stock rallies 24% on preclinical Alzheimer's dataMarch 19, 2024 | prnewswire.comHoth Therapeutics Announces Positive Data In Completed Study of Alzheimer's Disease Pre-Clinical Treatment with HT-ALZFebruary 29, 2024 | finance.yahoo.comHoth Therapeutics Retains Venable LLP to Expand Its Patent PortfolioFebruary 26, 2024 | finanznachrichten.deHoth Therapeutics, Inc.: Hoth Therapeutics Engages Altasciences to Perform Key Study for HT-KIT Cancer Fighting TherapeuticFebruary 26, 2024 | markets.businessinsider.comHoth Therapeutics Partners Altasciences For Study On HT-KIT Cancer TreatmentFebruary 26, 2024 | prnewswire.comHoth Therapeutics Engages Altasciences to Perform Key Study for HT-KIT Cancer Fighting TherapeuticFebruary 13, 2024 | finance.yahoo.comHoth Therapeutics to Attend BIO CEO and Investor Conference, February 26-27, 2024February 6, 2024 | markets.businessinsider.comBuy Rating for Hoth Therapeutics: Promising HT-001 Prospects and Diverse Clinical PipelineJanuary 18, 2024 | finanznachrichten.deHoth Therapeutics, Inc.: Hoth Therapeutics Announces it Received FDA Approval to Expand HT-001 Clinical Trial to Treat Severely Ill PatientsJanuary 18, 2024 | markets.businessinsider.comHoth Therapeutics Received FDA Clearance To Broaden HT-001 Clinical TrialJanuary 18, 2024 | marketwatch.comHoth Therapeutics Shares Rise 14% After FDA Clearance for HT-001 Trial AmendmentsJanuary 18, 2024 | msn.comHoth stock jumps on FDA approval of study expansion for HT-001January 18, 2024 | finance.yahoo.comHoth Therapeutics Announces it Received FDA Approval to Expand HT-001 Clinical Trial to Treat Severely Ill PatientsDecember 27, 2023 | msn.comHoth Therapeutics, SCWorx among healthcare moversDecember 27, 2023 | msn.comWhy Hoth Therapeutics Shares Are Rising TodaySee More Headlines Receive HOTH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Hoth Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/10/2021Today5/04/2024Next Earnings (Estimated)5/20/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:HOTH CUSIPN/A CIK1711786 Webwww.hoththerapeutics.com Phone(646) 756-2997FaxN/AEmployees2Year FoundedN/APrice Target and Rating Average Stock Price Target$4.00 High Stock Price Target$4.00 Low Stock Price Target$4.00 Potential Upside/Downside+230.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($4.77) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-7,840,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-76.28% Return on Assets-66.79% Debt Debt-to-Equity RatioN/A Current Ratio13.89 Quick Ratio13.89 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.03 per share Price / Book0.60Miscellaneous Outstanding Shares4,890,000Free Float4,728,000Market Cap$5.92 million OptionableNot Optionable Beta0.65 (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesMr. Robb Knie (Age 55)President, CEO & Chairman Comp: $844.01kMr. David S. Briones (Age 48)Chief Financial Officer Ms. Hayley SpringerExecutive Vice President of OperationsKey CompetitorsKintara TherapeuticsNASDAQ:KTRAProtagenic TherapeuticsNASDAQ:PTIXYumanity TherapeuticsNASDAQ:YMTXiBioNYSE:IBIOKinetaNASDAQ:KAView All Competitors HOTH Stock Analysis - Frequently Asked Questions Should I buy or sell Hoth Therapeutics stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Hoth Therapeutics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" HOTH shares. View HOTH analyst ratings or view top-rated stocks. What is Hoth Therapeutics' stock price target for 2024? 1 Wall Street analysts have issued 1-year price targets for Hoth Therapeutics' shares. Their HOTH share price targets range from $4.00 to $4.00. On average, they expect the company's share price to reach $4.00 in the next year. This suggests a possible upside of 230.6% from the stock's current price. View analysts price targets for HOTH or view top-rated stocks among Wall Street analysts. How have HOTH shares performed in 2024? Hoth Therapeutics' stock was trading at $1.44 at the beginning of 2024. Since then, HOTH shares have decreased by 16.0% and is now trading at $1.21. View the best growth stocks for 2024 here. Are investors shorting Hoth Therapeutics? Hoth Therapeutics saw a decline in short interest in the month of April. As of April 15th, there was short interest totaling 146,600 shares, a decline of 32.8% from the March 31st total of 218,100 shares. Based on an average daily trading volume, of 428,000 shares, the days-to-cover ratio is currently 0.3 days. Currently, 3.4% of the company's shares are short sold. View Hoth Therapeutics' Short Interest. When is Hoth Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our HOTH earnings forecast. How were Hoth Therapeutics' earnings last quarter? Hoth Therapeutics, Inc. (NASDAQ:HOTH) announced its earnings results on Wednesday, November, 10th. The company reported ($3.50) EPS for the quarter, missing the consensus estimate of ($3.38) by $0.13. When did Hoth Therapeutics' stock split? Hoth Therapeutics's stock reverse split before market open on Wednesday, October 26th 2022. The 1-25 reverse split was announced on Wednesday, October 26th 2022. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, October 26th 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. What other stocks do shareholders of Hoth Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Hoth Therapeutics investors own include Citius Pharmaceuticals (CTXR), Ocugen (OCGN), Fulcrum Therapeutics (FULC), Heat Biologics (HTBX), Tonix Pharmaceuticals (TNXP), AIM ImmunoTech (AIM), Aytu BioPharma (AYTU), Gilead Sciences (GILD), iBio (IBIO) and Nabriva Therapeutics (NBRV). When did Hoth Therapeutics IPO? Hoth Therapeutics (HOTH) raised $8 million in an IPO on Friday, February 15th 2019. The company issued 1,300,000 shares at a price of $5.50-$6.50 per share. Laidlaw & Company (UK) Ltd. acted as the underwriter for the IPO. How do I buy shares of Hoth Therapeutics? Shares of HOTH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:HOTH) was last updated on 5/4/2024 by MarketBeat.com Staff From Our PartnersBiden to Launch “FedNOW” [Move Your Money Now]Priority GoldCould Your Accounts Be Frozen?Allegiance GoldAutomatic Income (from home)Awesomely, LLCUrgent Nvidia WarningAltimetryGlobal crypto currency reset (41 major banks signed up)Stansberry ResearchJeff Bezos Just Humiliated Elon MuskInvestorPlaceForget Nvidia. This is the future of AIPorter & CompanyThe asset beating inflation by 4xColonial Metals Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Hoth Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
